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Through unknown mechanisms, insulin activates the
sterol regulatory element-binding protein (SREBP1c)
transcription factor to promote hepatic lipogenesis.
We find that this induction is dependent on the
mammalian target of rapamycin (mTOR) complex 1
(mTORC1). To further define the role of mTORC1 in
the regulation of SREBP1c in the liver, we generated
mice with liver-specific deletion of TSC1 (LTsc1KO),
which results in insulin-independent activation of
mTORC1. Surprisingly, the LTsc1KO mice are pro-
tected from age- and diet-induced hepatic steatosis
and display hepatocyte-intrinsic defects in SREBP1c
activation and de novo lipogenesis. These pheno-
types result from attenuation of Akt signaling driven
by mTORC1-dependent insulin resistance. There-
fore, mTORC1 activation is not sufficient to stimulate
hepatic SREBP1c in the absence of Akt signaling,
revealing the existence of an additional downstream
pathway also required for this induction. We provide
evidence that this mTORC1-independent pathway
involves Akt-mediated suppression of Insig2a,
a liver-specific transcript encoding the SREBP1c
inhibitor INSIG2.
INTRODUCTION
The liver is a keyorgan in the systemic response to insulin, control-
ling both glucose and lipid metabolism. Hepatocytes respond to
insulin by halting gluconeogenesis and increasing de novo lipid
synthesis. Genetic mouse models have demonstrated that both
of these responses to insulin occur, at least in part, downstream
of the protein kinase Akt2 (Cho et al., 2001; Garofalo et al., 2003;
Leavens et al., 2009). Akt2 mediates these effects primarily
through the regulation of two downstream transcription factors,
FOXO1 and SREBP1c, which control the expression of the meta-
bolic enzymes underlying these processes (Figure S1A). FOXO1
stimulates gluconeogenic gene expression in the liver and isdirectly phosphorylated and inhibited by Akt (Gross et al., 2009).
While the mechanisms are less well characterized, Akt signaling
appears to stimulate denovo lipid synthesis through theactivation
of SREBP isoforms (reviewed in Krycer et al., 2010). SREBP1c is
the dominant insulin-stimulated isoform in the liver, responsible
for inducing lipogenic gene expression and promoting fatty acid
synthesis (Horton et al., 2002). Akt activation appears to be both
necessary and sufficient for the induction of hepatic SREBP1c
and lipid accumulation (Fleischmann and Iynedjian, 2000;
Leavens et al., 2009; Ono et al., 2003). An important feature of
hepatic insulin signaling is that control of gluconeogenesis and
lipogenesis is differentially affected under pathological conditions
of insulin resistance associated with type 2 diabetes. Under such
conditions, insulin fails to suppress glucose production by the
liver, while the induction of hepatic lipogenesis is sustained,
thereby contributing to both the hyperglycemic and hyperlipi-
demic states. Understanding this pathological phenomenon,
referred to as selective insulin resistance (Brown and Goldstein,
2008), requires a deeper understanding of how insulin and Akt
regulate hepatic lipid metabolism.
Recent cell-based studies have implicated the activation of
mTOR complex 1 (mTORC1) downstream of Akt in the induction
of SREBP isoforms (Du¨vel et al., 2010; Porstmann et al., 2008).
The primary mechanism by which Akt activates mTORC1 is
through the phosphorylation and inhibition of the TSC2 protein
within the TSC1-TSC2 complex (reviewed in Huang and
Manning, 2009). This protein complex acts as a GTPase-
activating protein (GAP) for a Ras-related small G protein called
Rheb, thereby enhancing its conversion to the GDP-bound off
state. GTP-bound Rheb stimulates mTORC1 kinase activity
and downstream signaling. Therefore, Akt-mediated inhibition
of the TSC1-TSC2 complex serves to activate Rheb and
mTORC1. Importantly, increased activation ofmTORC1, through
the expression of an activated allele of Akt (Porstmann et al.,
2008) or genetic disruption of the TSC1-TSC2 complex (Du¨vel
et al., 2010), has been found to activate SREBP isoforms
and promote an SREBP-dependent increase in de novo lipid
synthesis. Furthermore, a recent study has shown that the ability
of insulin to stimulate SREBP1c in rat hepatocytes is sensitive to
the mTORC1-specific inhibitor rapamycin (Li et al., 2010).
SREBP1c regulation is quite complex (Goldstein et al., 2006;
Raghow et al., 2008). The protein is synthesized as an inactiveCell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc. 21
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activating protein (SCAP) in the endoplasmic reticulum (ER)
membrane, where it is sequestered through the interaction of
SCAPwith INSIGproteins. Through a poorly understood process,
insulin stimulates trafficking of the SREBP1c-SCAP complex to
the Golgi, where SREBP1c is proteolytically processed to
generate the active transcription factor. The active form of
SREBP1c is sensitive to proteasomal degradation but can enter
the nucleus to engage its transcriptional targets, including its
own gene promoter and those encoding the major enzymes of
fatty acid synthesis (Horton et al., 2002). A collection of previous
studies has implicated insulin and Akt in controlling different
aspects of SREBP1c activation (Krycer et al., 2010). While the
mechanisms remain to be determined, mTORC1 signaling down-
streamof Akt appears to regulate someaspect of the trafficking or
processing of SREBP isoforms, without obvious effects on trans-
lation or stability (Du¨vel et al., 2010; Porstmann et al., 2008).
The role of mTORC1 activation in the metabolic response of
the liver to insulin and nutrients is poorly understood (Howell
and Manning, 2011). Elevated levels of mTORC1 signaling
have been associated with conditions of hepatic insulin resis-
tance (Khamzina et al., 2005; Koketsu et al., 2008; Mordier and
Iynedjian, 2007). In vitro, mTORC1 signaling can cause cell-
intrinsic insulin resistance through negative feedback mecha-
nisms affecting upstream regulators of Akt (Dibble et al., 2009;
Harrington et al., 2005). In support of an in vivo role for these
feedback mechanisms controlling insulin sensitivity, knockout
of S6K1, a downstream target activated by mTORC1, leads to
an increased response of Akt signaling to insulin in the mouse
liver, as well as other metabolic tissues (Um et al., 2004).
However, the phenotype of the S6K1 knockout mouse is
confounded by a pronounced reduction in adiposity. Therefore,
liver-specific genetic models are needed to better define the
hepatocyte-intrinsic roles of mTORC1 in controlling insulin
signaling and lipogenesis.
Here, we seek to elucidate the role of mTORC1 signaling in the
regulation of SREBP1c and lipid metabolism in the liver. We find
that mTORC1 activation is required for the induction of hepatic
SREBP1c in response to insulin and feeding. To determine
whether mTORC1 activation is sufficient to drive hepatic
lipogenesis, we generate an mTORC1 gain-of-function mouse
model lacking TSC1 in the liver. Contrary to our prediction, these
mice are protected from both age- and diet-induced hepatic
steatosis. In determining the mechanism of this protection, we
find that there is a surprising defect in the induction of SREBP1c
in the livers of these mice, stemming from the attenuation of
hepatic Akt signaling. These findings indicate that mTORC1
activity alone cannot stimulate lipogenesis in the liver and that
a second Akt-driven pathway is also required. Finally, our data
indicate that the mTORC1-independent pathway downstream
of Akt involves the suppression of a liver-specific isoform of
INSIG (Yabe et al., 2003; Yellaturu et al., 2005, 2009).
RESULTS
Insulin Stimulates Hepatic SREBP1c
in an mTORC1-Dependent Manner
As the mechanism of hepatic SREBP1c induction by insulin and
Akt is poorly understood, we sought to determine whether22 Cell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc.mTORC1 activity contributes to this induction in primary mouse
hepatocytes. Insulin stimulates activating phosphorylation
events on Akt, leading to subsequent phosphorylation of the
Akt targets FOXO1, FOXO3a, and TSC2, the latter target of
which leads to mTORC1 activation and phosphorylation of
S6K1 (Figures 1A and S1A). As described for other cell types,
we find that inhibition of mTORC1 with rapamycin enhances
the insulin-stimulated phosphorylation of Akt and its substrates
in hepatocytes (Figure 1A), presumably through inhibition of
negative feedback mechanisms (reviewed in Harrington et al.,
2005; Huang and Manning, 2009). In response to insulin,
SREBP1c induces its own expression, as well as genes encod-
ing lipogenic enzymes, such as FASN (Horton et al., 2002;
Raghow et al., 2008). Importantly, despite enhancing Akt
signaling, pretreatment with rapamycin suppressed the ability
of insulin to stimulate Srebp1c and Fasn (Figure 1B). In contrast,
mRNA expression of Igfbp1 and the gluconeogenic enzyme
Pepck, two canonical FOXO1 targets, was inhibited by insulin
but not affected by rapamycin (Figure S1B). These findings are
consistent with those described recently for rat hepatocytes
(Li et al., 2010) and demonstrate that mTORC1 is required for
proper insulin stimulation of SREBP1c. Consistent with this
effect on SREBP1c, rapamycin also significantly impairs the
ability of insulin to stimulate de novo lipid synthesis in hepato-
cytes (Figure 1C). To determine the relevance of these findings
in vivo, we subjected mice to an overnight fast, followed by re-
feeding. Feeding activates hepatic Akt and mTORC1 signaling
and promotes the expression and processing of SREBP1 and
increased expression of its targets (Figures 1D and 1E) (Horton
et al., 1998). Importantly, SREBP1c activation was blocked by
treatment with rapamycin just prior to feeding (Figures 1D and
1E), without effects on FOXO1 targets (Figure S1C). Taken
together with studies in other settings (Du¨vel et al., 2010;
Porstmann et al., 2008), these results indicate that mTORC1 is
a critical effector downstream of insulin and Akt for the induction
of SREBP1c in hepatocytes.
Liver-Specific Deletion of Tsc1 Results
in Insulin-Independent Activation of mTORC1
To further define the role of mTORC1 in the regulation of hepatic
lipid metabolism, we employed a liver-specific gain of function
model to disconnect mTORC1 activation from its normal control
by insulin. As insulin signals to mTORC1 through Akt-mediated
inhibition of the TSC1-TSC2 complex, loss of TSC1 or TSC2
leads to Akt-independent activation of mTORC1 signaling. To
delete Tsc1 specifically in hepatocytes, we used a previously
described floxed allele of Tsc1 (Tsc1fl) (Figure 2A) (Kwiatkowski
et al., 2002), backcrossed onto a pure C57BL/6J background.
Following Cre-induced recombination, exons 17 and 18 of the
Tsc1fl allele are deleted, and this has been demonstrated to
generate a null allele (Kwiatkowski et al., 2002). Hepatocyte-
specific deletion of this allele was achieved by crossing these
mice to those expressing Cre from the albumin promoter
(Alb-Cre) (Postic and Magnuson, 2000). Genomic appearance
of the null allele and liver-specific loss of TSC1 protein were
confirmed by PCR genotyping (Figure 2B) and immunoblotting
(Figure 2C), respectively, of liver extracts from littermates of
different genotypes. Mice with homozygous loss of Tsc1 in their
livers (Alb-Cre Tsc1fl/fl, referred to as LTsc1KO) were born at
Figure 1. mTORC1 Activity Is Required for the
Insulin-Stimulated Induction of Hepatic SREBP1c
and De Novo Lipogenesis
(A) Primary hepatocytes were serum starved overnight,
pretreated for 30 min with vehicle or rapamycin (Rap;
20 nM), and stimulated for 6 hr with insulin (Ins; 10 nM), as
indicated.
(B) Hepatocytes were treated as in (A), and mRNA
expression was measured by qRT-PCR. Transcript levels
are shown relative to untreated controls. *p < 0.006
(Srebp1c) and p < 4 3 107 (Fasn) compared to un-
stimulated; **p < 0.03 (Srebp1c) and p < 0.002 (Fasn)
compared to insulin-stimulated, vehicle-treated.
(C) Hepatocytes treated as in (A) were labeled with 14C
acetate, and the levels of 14C incorporation into the lipid
fraction are shown relative to untreated controls. *p < 53
105 and **p < 0.004 for the comparisons described in (B).
Data are presented as the mean ± SEM from three (B) or
four (C) independent experiments.
(D and E) Eight-week-old mice were fasted overnight ()
and then refed for 6 hr (+) following a 30 min pretreatment
with vehicle or rapamycin (10 mg/kg). N = 4 mice per
condition. Liver lysates were immunoblotted for markers
of mTORC1 signaling and full-length (fl) and processed (p)
SREBP1 (D). Gene expression was measured by qRT-
PCR (E). Data are shown as mean ± SEM relative to
untreated controls. *p < 0.003 (Srebp1c), p < 0.002 (Fasn),
and p < 0.0007 (Scd1) compared to fasted; **p < 0.03
(Srebp1c), p < 0.05 (Fasn), and p < 0.0001 (Scd1)
compared to fed, vehicle-treated.
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of age. As TSC1 stabilizes TSC2, LTsc1KO livers also exhibit
a near-complete loss of TSC2 protein (Figure 2C). Importantly,
only LTsc1KO livers exhibited increased phosphorylation of S6
and 4EBP1, reflected by decreased electrophoretic mobility,
which are common readouts of mTORC1 signaling (Figures 2C
and 2D). Hepatic mTORC1 signaling was sustained even under
fasting conditions in the LTsc1KO mice, and the level of activa-
tion was comparable to control Tsc1fl/fl mice just after feeding
(Figure 2E). Likewise, primary hepatocytes isolated from
LTsc1KO mice exhibited insulin-independent activation ofCell MetabolismTORC1 signaling (Figure 2F). Therefore, the
LTsc1KO mice provide a model of hepatic
mTORC1 activation that occurs independent
of the upstream insulin-signaling pathway.
LTsc1KO Mice Are Protected from Age-
and Diet-Induced Hepatic Steatosis
To begin to understand the role of mTORC1
signaling in the control of hepatic lipid metabo-
lism, we examined the histological features of
livers from cohorts of Tsc1fl/fl and LTsc1KO
mice. Contrary to our expectations, LTsc1KO
mice were protected from age-induced hepatic
steatosis at 9 months, exhibiting significantly
lower levels of liver triglycerides (TGs) (Figures
S1A–S1C). A relative decrease in lipid accumu-
lation in LTsc1KO livers was also evident in
H&E-stained liver sections at 6 months (e.g.,
see Figure 2D). Given the surprising decreasein lipid accumulation in the livers of LTsc1KO mice fed a normal
chow diet, we challenged the LTsc1KO mice with a lard-based
high-fat diet (HFD) to further examine this phenotype. As on
a chow diet (data not shown), there was no significant difference
in weight gain between the Tsc1fl/fl and LTsc1KOmice on a HFD
(Figure 3A). Dual-energy X-ray absorptiometry (DEXA) indicated
that there was no difference in percentage body fat after
16 weeks of HFD (Figure 3B). However, the LTsc1KO mice
exhibited protection from HFD-induced hepatic steatosis
(Figure 3C). Blinded scoring of liver sections by a pathologist
indicated that all Tsc1fl/flmice had moderate to severe steatosis,m 14, 21–32, July 6, 2011 ª2011 Elsevier Inc. 23
Figure 2. Liver-Specific Tsc1 Deletion Renders Hepatic mTORC1
Signaling Constitutive and Insulin Independent
(A) Schematic of the Tsc1fl allele and resulting null allele following Cre-medi-
ated excision. The positions of the three PCR primers used for genotyping are
shown with arrows.
(B) Representative PCR genotyping of liver tissue from the offspring of a cross
between Tsc1fl/fl and Albumin (Alb)-Cre Tsc1fl/+ mice using the primers shown
in (A). Genomic DNA fromMEFs of the given genotype was used as controls for
the three Tsc1 alleles.
(C) Immunoblots of liver, muscle, and fat tissue extracts from ad libitum-fed
mice of the given genotypes are shown.
(D) Immunohistochemistry of phospho-S6 (S240/244) and staining with
hematoxylin and eosin (H&E) were performed on adjacent liver sections from
ad libitum-fed, 6-month-old mice of the given genotypes.
(E) Eight-week-old Tsc1fl/fl and LTsc1KO mice were fasted overnight () and
then refed for 6 hr (+) where indicated (n = 3 mice per condition). Immunoblots
of liver extracts from these mice are shown.
(F) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice were serum-starved
overnight and stimulated for 6 hr with insulin (Ins; 10 nM) in the presence or
absence of a 30 min pretreatment with rapamycin (Rap; 20 nM).
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lipid accumulation (Figure 3D). Consistent with these histological
findings, LTsc1KO livers had significantly reduced levels of TGs
(Figure 3E). Therefore, constitutive mTORC1 signaling in the
LTsc1KO livers is accompanied by a decrease, rather than the
predicted increase, in hepatic lipid accumulation.24 Cell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc.LTsc1KO Mice Have Defects in Hepatic Induction
of SREBP1c and Lipogenesis
To determine the mechanism of protection from hepatic steato-
sis in the LTsc1KO mice, we examined candidate pathways
involved in lipid mobilization and metabolism. For instance,
increased TG export could account for decreased accumulation
in the liver. However, serum levels of TGs, nonesterified fatty
acids (NEFAs), and cholesterol were not significantly different
in mice fed a HFD, but TG and NEFA levels trended down in
LTsc1KO compared to Tsc1fl/fl mice (Figure S2D). Furthermore,
LTsc1KO mice did not display significant differences in hepatic
TG output under fasting conditions, and again, these levels
trended lower relative to controls (Figure S2E). Consistent with
the lack of physiological evidence supporting a role for increased
TG mobilization, transcript levels of proteins involved in these
processes, such as Mttp, Dgat1, and Dgat2, were not signifi-
cantly changed in LTsc1KO livers (Figure 3F). To address the
possibility that LTsc1KO livers burn more lipid than controls,
we measured expression of genes important for the b-oxidation
of fatty acids. We found that transcript levels of Ppara, Mcad,
and Cpt1a were not increased in the LTsc1KO livers, and in
fact, Mcad expression was significantly reduced in these livers
relative to controls (Figure 3G). This is consistent with recent
findings that mTORC1 signaling decreases the expression of
b-oxidation genes in the liver (Sengupta et al., 2010). As mito-
chondria are themajor site of b-oxidation andmTORC1 signaling
has been proposed to promote mitochondrial biogenesis
(Cunningham et al., 2007), we also measured levels of mitochon-
drial markers. However, transcripts encoding the major mito-
chondrial transcription factor TFAM and the mitochondrial
enzymes COX-IV and citrate synthase were not different (Fig-
ure S2F). Collectively, these results suggest that neither an
increase in hepatic lipid output nor consumption underlies the
protection from steatosis exhibited by the LTsc1KO mice.
Previous studies have demonstrated that mTORC1 signaling
can drive lipogenesis through activation of SREBP isoforms
(Du¨vel et al., 2010; Porstmann et al., 2008), and a similar role in
the liver is supported by our findings above (Figure 1). However,
like LTsc1KO mice, Srebp1 knockout mice are protected from
hepatic steatosis despite normal increases in adiposity (Yahagi
et al., 2002). Therefore, we considered the possibility that
LTsc1KO livers might have a defect in SREBP1c induction that
could account for their decreased TG levels. Indeed, we found
that the expression of Srebp1c and its lipogenic targets, Fasn
and Scd1, were significantly reduced in the livers of LTsc1KO
mice (Figure 4A). Consistent with a defect in SREBP1c activa-
tion, a more pronounced decrease in the levels of processed,
active SREBP1 relative to full-length, inactive SREBP1 was
detected in the LTsc1KO livers (Figure 4B). Reduced levels of
FASN and SCD1 protein were also evident in these livers. The
differences in lipogenic gene expression were not restricted to
the HFD-fed group, but were also detected in young mice
(8 weeks) fed a normal chow diet (Figure S3A). Furthermore,
young LTsc1KOmice displayed defects in the hepatic induction
of processed SREBP1 in response to feeding (Figure 4C). The
decreased ratio of processed to full-length SREBP1 in the
LTsc1KO livers is also reflected in decreased induction of its lipo-
genic targets at the protein and transcript levels (Figures 4C and
4D). LTsc1KO mice also exhibit defects in the feeding-induced
Figure 3. LTsc1KO Mice Are Protected from Diet-Induced Hepatic Steatosis
(A) A cohort of male Tsc1fl/fl (n = 3) and LTsc1KO (n = 4) mice were weighed between the ages of 5 and 25 weeks, while being fed a high-fat diet (HFD) for the final
16 weeks.
(B) HFD-fed male Tsc1fl/fl (n = 6) and LTsc1KO (n = 6) mice were subjected to DEXA scanning. In (A) and (B), data are presented as the mean ± SEM.
(C andD) Liver sections from 6-month-old Tsc1fl/fl (n = 7) and LTsc1KO (n = 7) mice fed aHFD, as in (A), were stainedwith H&E. Representative sections from these
mice are shown (scale bars: 500 mm [403], 50 mm [2003]) (C). The results from blinded scoring of the H&E-stained liver sections for negative/mild, moderate, or
severe steatosis are provided (D).
(E) Liver triglycerides (TGs) weremeasured in ad libitum-fed Tsc1fl/fl (n = 5) and LTsc1KO (n = 5) mice on a HFD, as in (A). TG levels are shown normalized to protein
concentration and are presented as the mean ± SEM. *p < 0.05.
(F and G) Expression of mRNA in the livers of ad libitum-fed Tsc1fl/fl (n = 4) and LTsc1KO (n = 4) mice on a HFD, as in (A), was measured by qRT-PCR for the given
genes, and levels are presented as mean ± SEM relative to Tsc1fl/fl. *p < 0.05 (Mcad).
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and Hmgcr (Figure S3B) (Horton et al., 2002). Importantly,
a hepatocyte-intrinsic defect in the induction of de novo lipid
synthesis is detected in primary hepatocytes from LTsc1KO
livers (Figure 4E), and there was a corresponding defect in the
insulin-stimulated expression of Srebp1c and its target Fasn
(Figure 4F). Taken together with our previous findings, these
data indicate that mTORC1 activation is required but not suffi-
cient to induce SREBP1c and lipogenesis in hepatocytes andsuggest that defects in the induction of SREBP1c might underlie
the protection of LTsc1KO mice from hepatic steatosis.
Elevated Hepatic mTORC1 Signaling Attenuates Insulin
Signaling to Akt
Decreases in hepatic lipid accumulation and steatosis accom-
panied by decreases in SREBP1c and de novo lipogenesis are
phenotypes described for the liver-specific knockout of Akt2
(Leavens et al., 2009). It has been well established in cellCell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc. 25
Figure 4. LTsc1KO Livers and Hepatocytes Have
Defects in the Induction of SREBP1c Expression
and De Novo Lipogenesis
(A) Expression of mRNA in the livers of male ad libitum-fed
Tsc1fl/fl (n = 4) and LTsc1KO (n = 4) mice on a HFD was
measured by qRT-PCR for the given genes, and levels are
presented as mean ± SEM relative to Tsc1fl/fl. *p < 0.005
(Srebp1c), p < 0.05 (Fasn), and p < 0.004 (Scd1).
(B) Immunoblots of full-length (fl) and processed (p)
SREBP1, FASN, and SCD1 are shown in liver lysates from
mice described in (A).
(C and D) Eight-week-old Tsc1fl/fl and LTsc1KOmice were
fasted overnight () with or without refeeding for 6 hr (+) as
indicated (n = 4 per condition). Liver lysates from Tsc1fl/fl
and LTsc1KO mice were immunoblotted for full-length (fl)
and processed (p) SREBP1 and its targets. The ratio of
SREBP1(p) to SREBP1(fl) in the fasted and refed state was
quantified for both genotypes and is presented as mean ±
SEM relative to fasted wild-type samples. *p < 0.01 for the
fold induction by feeding compared to Tsc1fl/fl livers (C).
RNA was isolated from the livers of these mice, and gene
expression was measured by qRT-PCR and is shown as
mean ± SEM relative to fasted samples for each genotype.
*p < 0.0005 (Scd1) and p < 0.003 (Fasn) for the fold
induction by feeding compared to Tsc1fl/fl livers (D). Note:
There are no significant differences in fasted expression
levels between Tsc1fl/fl and LTsc1KO livers.
(E) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice
were serum starved overnight, followed by insulin stimu-
lation (Ins; 10 nM) for 6 hr. Cells were labeled with 14C
acetate for the final 4 hr, and its incorporation into the lipid
fractionwasmeasured. Data are presented as themean of
duplicate samples ± SEM relative to unstimulated wild-
type samples. *p < 0.01 for the fold induction by insulin
compared to Tsc1fl/fl hepatocytes.
(F) Expression of mRNA from primary hepatocytes treated
as described in (E) was analyzed by qRT-PCR for the given
genes, and levels are presented as the mean of duplicate
samples ± SEM relative to the unstimulated samples for
each genotype. *p < 0.013 (Srebp1c) and p < 0.023 (Fasn)
for the fold induction by insulin compared to Tsc1fl/fl
hepatocytes. Data in (E) and (F) are representative of at
least three independent experiments.
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feedback mechanisms that can dampen the response of cells
to insulin, resulting in decreased Akt signaling (reviewed in Har-
rington et al., 2005; Huang and Manning, 2009). However, it is
unknown whether mTORC1 activation in the liver can cause
hepatic insulin resistance. Indeed, LTsc1KO mice display
decreased phosphorylation of Akt and its downstream target
FOXO1 in their livers (Figure 5A). In contrast, phosphorylation
of GSK3a and b was not substantially different in Tsc1fl/fl and
LTsc1KO livers, consistent with the fact that additional protein
kinases can phosphorylate these Akt substrates (Cross et al.,26 Cell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc.1995; Eldar-Finkelman et al., 1995; Fang
et al., 2002; Zhang et al., 2006). Atypical
PKCs have also been implicated in the promo-
tion of hepatic lipogenesis downstream of the
insulin receptor (Matsumoto et al., 2003; Tani-
guchi et al., 2006). However, the activating
phosphorylation of PKCz/l was increased,
rather than decreased, in the LTsc1KO livers(Figure S4A), perhaps suggesting a compensatory mechanism.
As the AMP-dependent protein kinase (AMPK) has recently
been found to block the processing of SREBP isoforms
(Li et al., 2011), we also examined AMPK activation, but found
no difference between the control and LTsc1KO livers (Fig-
ure S4B). One feedback mechanism by which mTORC1 activa-
tion is thought to inhibit insulin signaling is through the
downregulation of IRS1 protein levels (reviewed in Harrington
et al., 2005), and indeed, IRS1 levels were reduced in LTsc1KO
livers (Figure 5A). As would be expected from the defect in
Akt-mediated phosphorylation of FOXO1, LTsc1KO mice
Figure 5. Attenuation of Akt Signaling in LTsc1KO
Livers and Hepatocytes Is Responsible for the
Defect in SREBP1c Induction
(A) Immunoblots of liver lysates from ad libitum-fed male
Tsc1fl/fl and LTsc1KO mice following a 16 week HFD are
shown for the indicated phospho- (P) and total proteins.
(B) Eight-week-old Tsc1fl/fl and LTsc1KO mice were fas-
ted overnight () with or without refeeding for 6 hr (+) as
indicated prior to immunoblot analysis of liver lysates.
(C) Primary hepatocytes from Tsc1fl/fl (+) and LTsc1KO ()
mice were serum starved overnight and then stimulated
with insulin (Ins; 10 nM) for 1 hr where indicated.
(D) Following overnight serum starvation, LTsc1KO
hepatocytes were treated with rapamycin (Rap; 20 nM) for
30 min where indicated prior to insulin stimulation (10 nM)
for 6 hr.
(E) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice
were infected with adenovirus expressing either empty
vector (Vec) or myr-Akt2 (Akt2), and 6 hr postinfection,
cells were serum starved overnight before lysis and
immunoblotting.
(F) Following overnight serum starvation, uninfected cells
were stimulated with insulin (10 nM) for 6 hr, whereas cells
infected as in (E) were left unstimulated. Cells were
labeled with 14C acetate for the final 4 hr, and its incor-
poration into the lipid fraction was measured. Data are
presented as the mean of duplicate samples ± SEM
relative to unstimulated Tsc1fl/fl samples for the unin-
fected group or to the vector-expressing Tsc1fl/fl samples
for the infected group and are representative of at least
two independent experiments. *p < 0.05 for the difference
in fold induction by insulin compared to Tsc1fl/fl hepato-
cytes.
(G) Primary hepatocytes were infected as described in (E),
with vector-expressing cells being treated with insulin
(10 nM) for 6 hr where indicated. Expression of mRNAwas
measured by qRT-PCR for the given genes, and levels are
presented as mean ± SEM relative to the unstimulated
vector-expressing group for each genotype (n = 3).
*p < 0.027 (Srebp1c) and p < 0.024 (Fasn) for the fold
induction by insulin compared to Tsc1fl/fl hepatocytes.
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FOXO1 targets Pepck and Igfbp1 (Figure S4C) and a decrease
in glucose tolerance (Figure S4D) relative to controls. However,
LTsc1KO mice do not display differences in insulin tolerance
(Figure S4E). Young LTsc1KO mice on a normal chow diet also
exhibit attenuation of Akt activation in response to feeding (Fig-
ure 5B). Finally, a cell-intrinsic reduction in the ability of insulin
to stimulate Akt was confirmed in primary hepatocytes from
LTsc1KO livers (Figure 5C), and this was rescued by pretreat-
ment with rapamycin (Figure 5D). The hepatocyte-intrinsic
defect in insulin sensitivity in LTsc1KO mice is further sup-
ported by the fact that there are no significant differences in
circulating insulin levels on either a normal chow or high-fat
diet (Figure S4F). Therefore, uncontrolled mTORC1 activity in
the liver causes defects in insulin signaling to Akt.Restoration of Akt Signaling to LTsc1KO Hepatocytes
Rescues SREBP1c Induction
To determine whether the mTORC1-dependent attenuation of
Akt signaling underlies the defect in the ability of insulin to stim-
ulate lipogenesis in LTsc1KO hepatocytes, we employed a
membrane-targeted constitutively active allele of Akt2 (myr-Akt2), which bypasses negative-feedback mechanisms acting
on upstream components in the pathway. Unlike endogenous
Akt (Figure 5C), adenovirally delivered myr-Akt2 is
phosphorylated to a similar extent in both Tsc1fl/fl and LTsc1KO
hepatocytes (Figure 5E). Interestingly, restoring Akt2 signaling to
LTsc1KO hepatocytes ameliorated their defect in lipogenesis.
Unlike insulin, myr-Akt2 stimulated similar levels of de novo lipid
synthesis in both Tsc1fl/fl and LTsc1KO hepatocytes (Figure 5F).
As expected from this rescue of lipogenesis, and in contrast to
insulin, myr-Akt2 also induced expression of Srebp1c and Fasn
to a similar extent in Tsc1fl/fl and LTsc1KO hepatocytes
(Figure 5G). These findings support a model in which Akt2
signaling is essential for the induction of hepatic SREBP1c and
lipogenesis and that, in addition to a requirement for mTORC1
activity, at least one additional parallel pathway downstream of
Akt2 is essential for this induction.INSIG2a Suppression Is an mTORC1-Independent
Mechanism Regulating SREBP1c Downstream of Akt
To gain insight into the mTORC1-independent mechanism of
SREBP1c induction downstream of Akt2, we examined the
regulation of candidate pathways. Akt and other kinasesCell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc. 27
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mTOR-Dependent and Independent Control of SREBP1cphosphorylate and inhibit GSK3a and b, which have been found
to regulate the stability of processed, active SREBP isoforms in
cell culture models (Sundqvist et al., 2005). However, unlike Akt
and FOXO1, we did not observe substantial differences in the
inhibitory phosphorylation of GSK3 in the livers or hepatocytes
of LTsc1KOmice (Figures 5A and S5A). Another potential candi-
date for SREBP1c regulation downstream of Akt is the LXR
family of nuclear receptors, which can transcriptionally activate
Srebp1c in response to insulin (Hegarty et al., 2005). However,
no significant differences in the expression of Lxra or Lxrb or their
canonical transcriptional target Abca1 were detected in the
LTsc1KO livers (Figure S5B).
Unlike hepatocytes, mTORC1 signaling is both necessary and
sufficient to activate SREBP isoforms in other cell types (Du¨vel
et al., 2010; Porstmann et al., 2008). Therefore, we decided to
investigate a mechanism of SREBP1c regulation that is believed
to be specific to the liver. Insulin signaling has been found to
suppress a liver-specific transcript encoding the SREBP-inhib-
itory protein INSIG2, called Insig2a (Yabe et al., 2003; Yellaturu
et al., 2005, 2009). As INSIG proteins can block the induction of
hepatic SREBP1c and lipogenesis (Engelking et al., 2004, 2005;
Takaishi et al., 2004), the suppression of Insig2a is likely to
contribute to the activation of SREBP1c in response to insulin
(Yabe et al., 2003). Interestingly, we found that LTsc1KO livers
express elevated levels of Insig2a transcripts and INSIG2
protein (Figures 6A and S5C). This is in contrast to Insig1, which
is a known transcriptional target of SREBP and, like other
targets, is reduced in the LTsc1KO livers (Figures S5C and
S5D). Consistent with the insulin-stimulated suppression of
Insig2a functioning in a parallel pathway to mTORC1, we found
that rapamycin does not affect Insig2a suppression in intact
livers or isolated hepatocytes from wild-type mice (Figures 6B
and 6C). However, an Akt-specific inhibitor (Aktviii) completely
reversed the suppression of Insig2a in response to feeding or
insulin, indicating that this mechanism occurs downstream of
Akt. The feeding-induced suppression of INSIG2 protein levels
was blocked in a dose-dependent manner by the Akt inhibitor
(Figure S5E). In contrast to the differential effects on Insig2a
expression, the Akt inhibitor and rapamycin have similar inhibi-
tory effects on the induction of SREBP1c processing and
expression (Figures S5F, 6B, and 6C). Consistent with the
elevated expression of Insig2a in LTsc1KO livers (Figure 6A),
LTsc1KO hepatocytes are defective in the suppression of
Insig2a in response to insulin (Figure 6D). Importantly, the resto-
ration of Akt signaling to LTsc1KO hepatocytes completely
rescues the suppression of Insig2a (Figure 6D). Consistent
with Akt-mediated downregulation of Insig2a being required
for proper Srebp1c induction, forced expression of Insig2 signif-
icantly decreased the ability of activated Akt to stimulate
Srebp1c, while having no effect on its suppression of the
FOXO1 target Igfbp1 (Figure S5G). Finally, siRNA-mediated
suppression of Insig2a in LTsc1KO hepatocytes restores the
insulin-stimulated induction of Srebp1c (Figure 6E), while main-
taining the defect in insulin-mediated suppression of Pepck
(Figure S5H). Collectively, these data are consistent with two
parallel pathways downstream of Akt2, one involving the
suppression of Insig2a expression and the other requiring
mTORC1 activation, both being essential for insulin-stimulated
induction of hepatic SREBP1c (Figure 6F).28 Cell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc.DISCUSSION
Recent genetic evidence suggests that Akt is a major effector of
insulin signaling for the induction of hepatic lipogenesis (Fleisch-
mann and Iynedjian, 2000; Leavens et al., 2009; Ono et al., 2003).
Whole-body and liver-specific knockouts of Akt2 are protected
from hepatic steatosis under conditions of obesity caused by
leptin deficiency (ob/ob) or a lard-based HFD (Leavens et al.,
2009). This phenotype is similar to that described for Srebp1
knockout mice, which are also protected from steatosis in the
background of obesity (Yahagi et al., 2002). Importantly, the
protection from hepatic lipid accumulation in the Akt2 knockout
models is accompanied by reduced expression of Srebp1c and
decreased de novo lipogenesis, suggesting that a defect in
SREBP1c induction underlies this phenotype. However, on
a coconut oil-based HFD with sucrose (Surwit), the liver-specific
Akt2 knockout mice do not exhibit defects in the expression of
Srebp1c or its lipogenic targets but maintain their reduced levels
of hepatic TGs. This suggests that SREBP1c-independent path-
ways downstream of Akt might also contribute to hepatic lipid
content. Interestingly, mice with liver-specific deletion of Pten,
which exhibit constitutive activation of Akt signaling, develop
severe hepatic steatosis on a normal chow diet (He et al.,
2010; Stiles et al., 2004), and this phenotype is dependent on
Akt2 and its regulation of lipogenic gene expression downstream
of SREBP1c (He et al., 2010). Likewise, hepatic expression of
constitutively active Akt also induces SREBP1c and causes fatty
liver disease and hypertriglyceridemia (Ono et al., 2003), much
like transgenic overexpression of SREBP1c itself (Shimano
et al., 1997). While studies have indicated that atypical PKCs
might play a parallel role (Matsumoto et al., 2003; Taniguchi
et al., 2006), these collective findings demonstrate that Akt is
a major insulin-responsive effector in the induction of hepatic
SREBP1c. While this regulation appears to contribute to both
physiological and pathological hepatic lipid accumulation, the
critical mechanisms downstream of Akt are not well defined.
Together with a recent study in rats (Li et al., 2010), our current
findings indicate that mTORC1 is an essential downstream
target of insulin and Akt signaling for the proper induction of
SREBP1c and lipogenesis in the liver. However, the LTsc1KO
mouse model demonstrates that mTORC1 activation alone is
not sufficient to induce SREBP1c.Wewere particularly surprised
to find that chronic mTORC1 signaling, instead, leads to
a decrease in the induction of SREBP1c and lipogenesis and
protection from both age- and diet-induced hepatic steatosis.
The decreased activation of SREBP1c in LTsc1KO hepatocytes
is the result of mTORC1-driven inhibitory feedback mechanisms
causing insulin resistance and attenuation of Akt signaling to its
other downstream pathways. Due to the disconnect between
Akt and mTORC1 signaling in these mice, the LTsc1KO model
affords a unique experimental system in which to identify
mTORC1-independent pathways and processes downstream
of Akt in the liver. Analyses of the LTsc1KO mice revealed that
Akt stimulates hepatic SREBP1c and lipogenesis through
parallel mTORC1-dependent and independent pathways and
that the latter pathway involves suppression of a liver-specific
inhibitor of SREBP1c.
Although functionally similar, distinct mechanisms regulate
the expression and stability of INSIG1 and INSIG2 (Goldstein
Figure 6. The mTORC1-Independent Pathway to
SREBP1c Involves Akt-Mediated Suppression of
Insig2a
(A) Expression of Insig2a in the livers of ad libitum-fed male
Tsc1fl/fl (n = 4) and LTsc1KO (n = 4) mice on a HFD was
measured by qRT-PCR, and levels are presented as
mean ± SEM relative to Tsc1fl/fl. *p < 0.0002.
(B) Eight-week-old mice were fasted overnight () and
then refed for 6 hr (+) following a 30 min pretreatment
with vehicle, rapamycin (Rap; 10 mg/kg), or Aktviii (Akti;
50 mg/kg) (n = 4 per condition). Hepatic RNA was isolated
and gene expression was measured by qRT-PCR. Data
are shown as mean ± SEM relative to fasted controls. *p <
3 3 106 (Insig2a) and p < 0.0002 (Srebp1c) compared to
fasted; **p < 0.01 and ***p < 0.0008 compared to vehicle-
treated fed mice. Note: There is no significant difference
between the fold suppression of Insig2a by refeeding in the
presence or absence of rapamycin or between Insig2a
levels in fasted mice versus those fed in the presence of
Aktviii.
(C) Tsc1fl/fl primary hepatocytes were serum starved
overnight and pretreated for 30 min with vehicle, rapa-
mycin (20 nM), or Aktviii (10 mM) prior to 6 hr stimulation
with insulin (Ins; 10 nM); gene expression was measured
by qRT-PCR. Data are presented as the mean of duplicate
samples ± SEM relative to unstimulated cells and are
representative of two independent experiments. Insig2a:
*p < 0.003 for insulin-stimulated suppression and p < 0.01
for insulin-stimulated suppression in the presence of
rapamycin. Note: There is no significant difference
between the fold suppression of Insig2a by insulin in the
presence or absence of rapamycin. Srebp1c: *p < 0.0003
compared to unstimulated; **p < 0.003 and ***p < 0.03
compared to vehicle-treated, insulin-stimulated samples.
(D) Primary hepatocytes from Tsc1fl/fl and LTsc1KO mice
were left uninfected or were infected with adenovirus
expressing either empty vector (Vec) or myr-Akt2 (Akt2),
and 6 hr postinfection, cells were serum starved overnight.
Uninfected cells were stimulated with insulin (10 nM) for
6 hr, whereas infected cells were left unstimulated. Insig2a
expression was measured by qRT-PCR. Data are
presented as the mean of duplicate samples ± SEM rela-
tive to the unstimulated samples for the uninfected group
or the vector-expressing samples for the infected group
for each genotype and are representative of at least two
independent experiments. *p < 0.05 compared to the fold
suppression by insulin in Tsc1fl/fl cells. The fold suppression of Insig2a induced byMyr-Akt2 in Tsc1fl/fl and LTsc1KO hepatocytes is not significantly different (NS).
(E) Tsc1fl/fl (Tsc1 +) and LTsc1KO (Tsc1 ) primary hepatocytes were transiently transfected with control or Insig2 siRNA. Twenty-four hours posttransfection,
cells were serum starved overnight, followed by a 6 hr stimulation with insulin (10 nM). Gene expression was measured by qRT-PCR, and levels are presented as
themean of duplicate samples ± SEM relative to unstimulated controls for each genotype. *p < 0.04 (Insig2a) and *p < 0.01 (Srebp1c) compared to the fold change
in response to insulin in Tsc1fl/fl hepatocytes treated with control siRNAs. The insulin-stimulated induction of Srebp1c in control siRNA-treated Tsc1fl/fl and Insig2
siRNA-treated LTsc1KO hepatocytes is not significantly different (NS).
(F) Model of two parallel pathways downstream of insulin and Akt2 required for the induction of hepatic SREBP1c and lipogenesis.
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of Insig1, and the INSIG1 protein is stabilized under sterol-rich
conditions, creating an autoinhibitory feedback mechanism
(Gong et al., 2006; Horton et al., 2003; Yang et al., 2002). In
contrast to INSIG1, the Insig2 gene is not transcriptionally regu-
lated by SREBP, and the INSIG2 protein ismuchmore stable and
unaffected by sterols. Importantly, the predominant liver-
specific transcript encoding INSIG2, referred to as Insig2a, is
strongly downregulated at the message level by insulin signaling
(Yabe et al., 2003), perhaps facilitating SREBP1c release from
the ER and its subsequent processing and activation. In this
study, we find that Akt is responsible for Insig2a suppressionby insulin and that this occurs independent of mTORC1
signaling. While the pathway by which Akt suppresses Insig2a
is currently unknown, our data indicate that this is a major
mTORC1-independent pathway downstream of Akt in the liver,
regulating SREBP1c activation. We hypothesize that the failure
to suppress Insig2a in LTsc1KO hepatocytes blocks the pathway
to SREBP1c activation at a step prior to that dependent on
mTORC1 signaling. Therefore, insulin induces SREBP1c pro-
cessing and activation through Akt-mediated suppression of In-
sig2a and stimulation of mTORC1 signaling, which both regulate
essential but distinct steps in the pathway to full activation of
SREBP1c. Future mechanistic studies are needed to defineCell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc. 29
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mTOR-Dependent and Independent Control of SREBP1cboth the signaling pathway by which Akt suppresses Insig2a
expression and the molecular target of mTORC1 signaling
involved in promoting SREBP1c activation.
EXPERIMENTAL PROCEDURES
Primary Hepatocyte Cultures
Primary hepatocytes were isolated from 7- to 9-week-old male mice
following portal vein collagenase perfusion (Blenzyme 3; Roche) and Percoll
gradient purification. For insulin stimulation experiments, hepatocyte cultures
were treated as described elsewhere (Li et al., 2010). Infection with adeno-
virus (Vector Biolabs) was performed 2 hr after plating at an moi of 10. After
6 hr infection, cells were washed once with PBS before serum starving
overnight prior to insulin stimulation. Nontargeting control and Insig2
siRNAs (ON-TARGETplus, Dharmacon) were transiently transfected into
primary hepatocytes 6 hr after plating using Lipofectamine 2000 (Invitrogen).
Twenty-four hours posttransfection, cells were serum starved overnight prior
to insulin stimulation.
Measurement of De Novo Lipogenesis
For the measurement of lipogenesis, primary hepatocytes were cultured and
treated as described above. For the final 4 hr of a 6 hr insulin stimulation, cells
were labeled with 1-14C acetic acid (Perkin Elmer). Cells were washed twice
with PBS before lysis in 0.5% Triton X-100. The lipid fraction was extracted
by the addition of chloroform and methanol (2:1 v/v) with vortexing, followed
by the addition of water with vortexing. Samples were centrifuged
(1000 rpm, 15 min), and 14C incorporation was measured in the bottom,
lipid-containing phase using a Beckman LS6500 scintillation counter. Each
condition was assayed in duplicate and normalized to protein concentrations
in the original lysates.
Gene Expression Analysis
For gene expression analyses, RNA was isolated from mouse tissue using
TRIzol (Invitrogen) and from primary hepatocytes using the RNeasy Mini Kit
(QIAGEN) and was reverse transcribed into cDNA using the Superscript III
First-Strand Synthesis System for RT-PCR kit (Invitrogen). SYBRGreen-based
quantitative RT-PCR was performed using an Applied Biosystems 7300 Real-
Time PCR System. Duplicate or triplicate samples were collected for each
experimental condition, and triplicate runs of each sample were normalized
to Rplp0 (m36b4) mRNA to determine relative expression levels. The
sequences for the primer pairs used in this study are listed in Table S1.
Immunoblotting and Immunohistochemistry
Lysates from cultured primary hepatocytes were prepared as previously
described (Manning et al., 2002). Tissue lysates were prepared from tissue
that was frozen in liquid nitrogen immediately following resection. Frozen
tissue samples were homogenized in NP-40 lysis buffer, and remaining debris
was cleared from lysates by subsequent 10 and 30 min spins at 16,0003 g. All
primary antibodies were obtained from Cell Signaling Technology, except
those to tubulin and actin (Sigma) and histone H1, SREBP1, INSIG1, and
INSIG2 (Santa Cruz). For immunohistochemistry, paraffin-embedded sections
were stained with phospho-S6 (S240/244) using a tissue staining kit (R&D
Biosystems).
Mouse Studies
Mice harboring the Tsc1fl allele on an FVB background were described previ-
ously (Kwiatkowski et al., 2002). For the current study, these mice were
crossed onto a C57BL/6J background through seven backcrosses. Alb-Cre
transgenic mice on this same background were described previously (Postic
and Magnuson, 2000). Study cohorts were generated by crossing Tsc1fl/fl
mice with Alb-Cre Tsc1fl/+ mice. PCR genotyping for Tsc1 and Cre was per-
formed as described (Kwiatkowski et al., 2002). Mice were fed either a normal
chow diet (9% kcal from fat) or a HFD (60% kcal from fat; F3282, Bio-serv). For
fasting-refeeding studies, mice were fasted overnight and either euthanized or
refed normal chow for 6 hr. Vehicle (5% Tween-80, 5% PEG-400 in 13 PBS),
rapamycin (10 mg/kg), or Aktviii (50 mg/kg; EMD) was administered via i.p.
injection 30 min prior to refeeding. Histological preparation and analyses30 Cell Metabolism 14, 21–32, July 6, 2011 ª2011 Elsevier Inc.were performed in the Dana-Farber/Harvard Cancer Center Rodent Histopa-
thology Core by R.T. Bronson, an expert rodent pathologist. Liver TGs were
measured by enzymatic assay using a kit and were normalized to protein
content. Body fat percentage was measured by DEXA (PIXImus).
Statistical Analyses
Statistical significance was measured using a Student’s two-tailed t test and
a statistical cutoff of p < 0.05. Data are presented asmean ± SEM. Immunoblot
quantification was performed using ImageJ software.
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